OpenURL Connection Search

Select item for more details and to access through your institution.

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Published in:
Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00928-9
By:
- He, Yonghan;
- Koch, Raphael;
- Budamagunta, Vivekananda;
- Zhang, Peiyi;
- Zhang, Xuan;
- Khan, Sajid;
- Thummuri, Dinesh;
- Ortiz, Yuma T.;
- Zhang, Xin;
- Lv, Dongwen;
- Wiegand, Janet S.;
- Li, Wen;
- Palmer, Adam C.;
- Zheng, Guangrong;
- Weinstock, David M.;
- Zhou, Daohong
Publication type:
Article
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Published in:
Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-022-01296-8
By:
- Khan, Sajid;
- Kellish, Patrick;
- Connis, Nick;
- Thummuri, Dinesh;
- Wiegand, Janet;
- Zhang, Peiyi;
- Zhang, Xuan;
- Budamagunta, Vivekananda;
- Hua, Nan;
- Yang, Yang;
- De, Umasankar;
- Jin, Lingtao;
- Zhang, Weizhou;
- Zheng, Guangrong;
- Hromas, Robert;
- Hann, Christine;
- Zajac-Kaye, Maria;
- Kaye, Frederic J.;
- Zhou, Daohong
Publication type:
Article
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Published in:
Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01241-3
By:
- Khan, Sajid;
- Wiegand, Janet;
- Zhang, Peiyi;
- Hu, Wanyi;
- Thummuri, Dinesh;
- Budamagunta, Vivekananda;
- Hua, Nan;
- Jin, Lingtao;
- Allegra, Carmen J.;
- Kopetz, Scott E.;
- Zajac-Kaye, Maria;
- Kaye, Frederic J.;
- Zheng, Guangrong;
- Zhou, Daohong
Publication type:
Article
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Published in:
Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01241-3
By:
- Khan, Sajid;
- Wiegand, Janet;
- Zhang, Peiyi;
- Hu, Wanyi;
- Thummuri, Dinesh;
- Budamagunta, Vivekananda;
- Hua, Nan;
- Jin, Lingtao;
- Allegra, Carmen J.;
- Kopetz, Scott E.;
- Zajac-Kaye, Maria;
- Kaye, Frederic J.;
- Zheng, Guangrong;
- Zhou, Daohong
Publication type:
Article
Senolytic treatment alleviates doxorubicin‐induced chemobrain.
Published in:
Aging Cell, 2024, v. 23, n. 2, p. 1, doi. 10.1111/acel.14037
By:
- Budamagunta, Vivekananda;
- Kumar, Ashok;
- Rani, Asha;
- Manohar Sindhu, Sahana;
- Yang, Yang;
- Zhou, Daohong;
- Foster, Thomas C.
Publication type:
Article
Effect of peripheral cellular senescence on brain aging and cognitive decline.
Published in:
Aging Cell, 2023, v. 22, n. 5, p. 1, doi. 10.1111/acel.13817
By:
- Budamagunta, Vivekananda;
- Kumar, Ashok;
- Rani, Asha;
- Bean, Linda;
- Manohar‐Sindhu, Sahana;
- Yang, Yang;
- Zhou, Daohong;
- Foster, Thomas C.
Publication type:
Article
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.
Published in:
Aging Cell, 2020, v. 19, n. 3, p. 1, doi. 10.1111/acel.13117
By:
- He, Yonghan;
- Li, Wen;
- Lv, Dongwen;
- Zhang, Xin;
- Zhang, Xuan;
- Ortiz, Yuma T.;
- Budamagunta, Vivekananda;
- Campisi, Judith;
- Zheng, Guangrong;
- Zhou, Daohong
Publication type:
Article
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Published in:
Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-15838-0
By:
- He, Yonghan;
- Zhang, Xuan;
- Chang, Jianhui;
- Kim, Ha-Neui;
- Zhang, Peiyi;
- Wang, Yingying;
- Khan, Sajid;
- Liu, Xingui;
- Zhang, Xin;
- Lv, Dongwen;
- Song, Lin;
- Li, Wen;
- Thummuri, Dinesh;
- Yuan, Yaxia;
- Wiegand, Janet S.;
- Ortiz, Yuma T.;
- Budamagunta, Vivekananda;
- Elisseeff, Jennifer H.;
- Campisi, Judith;
- Almeida, Maria
Publication type:
Article
Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging.
Published in:
Frontiers in Aging Neuroscience, 2024, p. 01, doi. 10.3389/fnagi.2024.1384554
By:
- Rani, Asha;
- Bean, Linda;
- Budamagunta, Vivekananda;
- Kumar, Ashok;
- Foster, Thomas C.
Publication type:
Article

Found: 9

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.

Co-targeting BCL-X<sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.

BCL-X<sub>L</sub> PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS<sup>G12C</sup>-mutated cancers.

BCL-X<sub>L</sub> PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS<sup>G12C</sup>-mutated cancers.

Senolytic treatment alleviates doxorubicin‐induced chemobrain.

Effect of peripheral cellular senescence on brain aging and cognitive decline.

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.

Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging.